De Novo Congestive Heart Failure After Kidney Transplantation: A Common Condition With Poor Prognostic Implications

Abstract Background: Large intracardiac bronchogenic cysts are rare mediastinal masses, however they must always be considered in the differential diagnosis of heart failure. Case Presentation: We present a 60-year-old female patient with de novo atrial fibrillation and heart failure, resulting from an incidental large intrapericardial mass. The patient underwent successful surgical resection, with pathological findings confirming a bronchogenic cyst.Conclusions: Large bronchogenic cysts located intrapericardially are very rare, however they should be included in the differential diagnosis of patients presenting with atrial fibrillation and heart failure.

Download Full-text

Lower risk of de novo congestive heart failure in peritoneal dialysis patients compared with hemodialysis patients

International Journal of Cardiology ◽

10.1016/j.ijcard.2016.10.066 ◽

2017 ◽

Vol 229 ◽

pp. 123 ◽

Cited By ~ 3

Author(s):

I-Kuan Wang ◽

Cheng-Li Lin ◽

Fung-Chang Sung

Keyword(s):

Heart Failure ◽

Congestive Heart Failure ◽

Peritoneal Dialysis ◽

Lower Risk ◽

De Novo ◽

Hemodialysis Patients ◽

Dialysis Patients

Download Full-text

Myocyte Replacement Therapy: Skeletal Myoblasts

Cell Transplantation ◽

10.3727/096368907783338226 ◽

2007 ◽

Vol 16 (9) ◽

pp. 971-975 ◽

Cited By ~ 15

Author(s):

Warren Sherman

Keyword(s):

Heart Failure ◽

Congestive Heart Failure ◽

De Novo ◽

Clinical Status ◽

Cardiovascular Effects ◽

Technical Difficulty ◽

Left Ventricular ◽

Skeletal Myoblasts ◽

Status Data

Skeletal myoblasts function as precursors to adult skeletal myocytes. More so than other muscle progenitors, their capacity for de novo self-renewal and their positive functional effects in the cardiac environment have been demonstrated, even though they do not attain a cardiomyocyte phenotype. Autologous skeletal myoblasts are easily procured by established methods and can be administered into diseased myocardium safely and without technical difficulty, features that at this time set them apart from any other myogenic cell. Clinical studies in patients with chronic myocardial disease have consistently reported modest improvements in ventricular function and clinical status. Data from the Myogenesis Heart efficiency and Regeneration Trial (MYOHEART) trial are currently being evaluated. Larger, randomized, placebo-controlled studies in patients with congestive heart failure due to postinfarction systolic left ventricular dysfunction are under way, such as Myoblast Autologous Grafting in Ischemic Cardiomayopathy (MAGIC) and Multicenter Study of the Safety and Cardiovascular Effects Of Myoblasts in Congestive Heart Failure (MARVEL). The future role of skeletal myoblasts in the clinical setting will be determined by the results of randomized trials as well as by the investigation of subsequent generations of myoblasts, engineered for enhanced efficacy.

Download Full-text

Abstract P039: Longitudinal measures of serial plasma phospholipid de novo lipogenesis fatty acids and incident congestive heart failure in older adults: The Cardiovascular Health Study

Circulation ◽

10.1161/circ.137.suppl_1.p039 ◽

2018 ◽

Vol 137 (suppl_1) ◽

Author(s):

Yujin Lee ◽

Heidi T Lai ◽

Marcia C de Oliveira Otto ◽

Rozenn N Lemaitre ◽

Xiaoling Song ◽

...

Keyword(s):

Heart Failure ◽

Older Adults ◽

Fatty Acids ◽

Congestive Heart Failure ◽

De Novo ◽

Plasma Phospholipid ◽

De Novo Lipogenesis ◽

Cardiovascular Health Study ◽

Longitudinal Changes ◽

Time Varying Covariates

Introduction: De novo lipogenesis (DNL) is an endogenous pathway for converting excess carbohydrates and proteins into fatty acids (FAs). While elevated DNL is linked to several metabolic abnormalities, little is known about associations of longitudinal changes in DNL FAs with incident congestive heart failure (CHF), a growing condition in older adults. Methods: We investigated relations of longitudinal changes in DNL FAs, measured at year 0, year 6, and year 13, with incident CHF using serial measures of plasma phospholipid myristic acid (14:0), palmitic acid (16:0), 7-hexadecenoic acid (16:1n-9), palmitoleic acid (16:1n-7), stearic acid (18:0), oleic acid (18:1n-9), and cis-vaccenic acid (18:1n-7). Time-varying covariates were measured using standardized methods in 2,005 older adults with two or more FA measures and free of CHF at baseline. Incident CHF was centrally adjudicated using medical records. Risk was assessed by multivariable-adjusted Cox proportional hazards. Results: During 14,628 person-years, 553 CHF events occurred. After multivariate adjustment, serial changes in 16:0, 16:1n-9, and 18:1n-7 were positively associated with incident CHF, with HRs (95% CI) for each 30% change in levels of 2.84 (1.50, 5.37), 1.16 (1.00, 1.33), and 1.42 (1.15, 1.77), respectively ( Table ). Findings were similar in sensitivity analyses excluding individuals with prevalent coronary heart disease (not shown). In analyses evaluating absolute, rather than changes in, DNL FA levels, the associations of 16:0, 16:1n-9, and 18:1n-7 with incident CHF were no longer statistically significant although with consistent directions of association (not shown). Neither changes nor absolute levels of 14:0, 16:1n-7, 18:0, and 18:1n-9 were associated with CHF. Conclusion: Serial changes in plasma phospholipid 16:0, 16:1n-9, and 18:1n-7 were associated with an elevated risk of CHF in older adults. These results indicate that potential mechanisms of risk, especially related to DNL, deserve further investigation.

Download Full-text